Assessment of vessels in the eye with glaucoma eye drop (Ripasudil Hydrochloride Hydrate ophthalmic solution)
Not Applicable
- Conditions
- Glaucoma
- Registration Number
- JPRN-UMIN000046665
- Lead Sponsor
- Fukui Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
Glaucoma allergic conjunctivitis Pregnant or nursing mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method width and flow rate of aqueous column Intraocular pressure at before and after usuing ophthalmic solution
- Secondary Outcome Measures
Name Time Method IOP reduction rate
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Ripasudil Hydrochloride's Rho kinase inhibition mechanism influence aqueous humor dynamics in glaucoma?
What comparative efficacy data exist for Ripasudil versus prostaglandin analogs in intraocular pressure reduction for primary open-angle glaucoma?
Which ocular biomarkers correlate with therapeutic response to Ripasudil in patients with elevated intraocular pressure?
What are the most frequently reported adverse events in Rho kinase inhibitor trials for glaucoma, and how are they managed clinically?
How do combination therapies involving Ripasudil and beta-blockers impact uveoscleral outflow in glaucoma treatment pathways?